bluuebunny/crossref_metadata_2025_split huggingface dataset:
Stenting very small coronary narrowings (< 2 mm) using the biocompatible phosphorylcholine‐coated coronary stent
Authors: Grenadier Ehud , Roguin Ariel , Hertz Izhack , Peled Benjamin , Boulos Monther , Nikolsky Eugenia , Amikam Shlomo , Kerner Arthur , Cohen Silviu , Beyar Rafael 
Published: August 2002

AbstractPublished data regarding stenting very small arteries are still limited. The BiodivYsio stent is a new stent coated with phosphorylcholine, a biocompatible molecule designed to reduce the formation of thrombus and potentially the risk of restenosis. The feasibility, safety, and efficacy of implantation of the 2.0 mm coated coronary stent were prospectively studied. We studied 97 patients from three centers who underwent elective, urgent, or bailout implantation of 106 BiodivYsio mini‐stents (2.0 mm) in 101 lesions. Forty percent of lesions had unfavorable characteristics (type B2 or C) and 16% had thrombus and/or chronic total occlusion. Successful stent deployment was achieved in 100/101 lesions (99%). MLD increased from 0.49 ± 0.31 mm to 1.89 ± 0.41 mm and diameter stenosis decreased from 89% ± 7% to 5.6% ± 6%. Small vessel stenting was the only procedure in 71% patients. There was one acute stent thrombosis case. During 6‐month follow‐up, none died, one had MI, and one was referred to CABG due to nontarget lesion progression. Angiographic restenosis that required target lesion revascularization was performed in 8/18 that had catheterization due to chest pain or significant ischemia. Most patients improved in their clinical symptoms. The rate of major adverse cardiac events was 4.1% at 30‐day and 10.3% at 6‐month follow‐up. This initial clinical experience indicates that the implantation of 2.0 mm stents coated with phosphorylcholine appears to be safe and efficacious in the treatment of complex coronary lesions and is associated with low target vessel revascularization rate in spite of the very small vessel diameter. Cathet Cardiovasc Intervent 2002;55:303–308. © 2002 Wiley‐Liss, Inc.
Long‐term clinical outcome after implantation of medium Palmaz (biliary) stents in very large native coronary arteries
Authors: Chio Francisco L. , Liu Ming W. , Al‐Saif Shukri M. , Khan Masroor A. , Lawson David , Al‐Mubarak Nadim 
Published: August 2002

AbstractIntracoronary stenting has been shown to improve acute and long‐term clinical results compared with coronary angioplasty. However, clinical outcome after medium Palmaz biliary (PB) stent implantation in very large native coronary arteries (> 4 mm in diameter) is unknown. This study evaluated restenosis and long‐term clinical outcome after PB stenting in large native coronary arteries. Between June 1993 and December 1998, 55 patients with 56 lesions were treated with PB stents. Intracoronary stent deployment was successful in all 56 vessels attempted (100%). The mean stenosis was reduced from 65% ± 10% to 4% ± 14%. In 48 of the 56 vessels (86%), vessel size was greater than 4.0 mm in diameter and the mean reference vessel diameter was 4.73 ± 0.7 mm after stenting. Angiographic success was achieved in 100%. Five patients had postprocedural cardiac enzyme elevation. There was no periprocedural death, emergency coronary artery bypass surgery, repeat target lesion revascularization, or acute stent thrombosis. Long‐term clinical follow‐up at mean of 28 ± 15 months was obtained in 96% of the patients. Clinical restenosis rate occurred in 18% of ostial (6/34) and 0% of nonostial (0/22) lesions (P < 0.0001) with an overall clinical restenosis rate of 11%. Repeat angioplasty were performed in these six patients. There were three cardiac and three noncardiac deaths. The overall event‐free survival at 1 and 3 years was 92% ± 4% and 80% ± 6%, respectively. PB stent implantation in very large native coronary arteries can be performed with a high degree of procedural success and low in‐hospital complications. The long‐term clinical outcome of patients undergoing PB stenting is associated with excellent event‐free survival. However, stenting of ostial lesions remains as an important factor for restenosis even in very large coronary artery stenting. Cathet Cardiovasc Intervent 2002;56:35–39. © 2002 Wiley‐Liss, Inc.
Comparison of low‐volume versus standard‐volume left ventriculography
Authors: Hodges Michael C. , Rollefson William A. , Sample Scott A. , Rubal Bernard J. , Stajduhar Karl C. 
Published: August 2002

AbstractLeft ventriculography provides useful information about cardiac function, wall motion, and mitral regurgitation (MR). However, standard volumes of contrast agent frequently are associated with ventricular ectopy. This study compares the use of low‐volume (Low‐vol) ventriculography to standard volume (Std‐vol) ventriculography. Left ventricular (LV) ejection fraction (EF), changes in LV end‐diastolic pressure (LVEDP), the incidence of ectopy, and >2+ MR were prospectively determined from the random order use of standard (15 mL/ second for 3 sec) and low‐volume (15 mL/sec for 1 sec) contrast agents in 102 patients. Each patient served as his or her own control. Twenty‐seven percent of the 204 ventriculograms were not interpretable due to ectopy. Ectopy ≥ 3 beats was more common with Std‐vol angiograms (41% vs. 14%, P < 0.001). Post‐injection LVEDP increased from baseline after both Std‐vol and Low‐vol injections (P <0.001). In patients for whom both angiograms could be interpreted (n = 58), no differences were noted between planimetered EFs (Low‐vol = 61 ± 20% vs. Std‐vol = 62 ± 20%, with r = 0.87; P < 0.001). A Bland‐Altman test of agreement indicated a mean difference ± 95% CI = −2 ± 19%. Low‐volume ventriculography reduces contrast load and ectopy while providing similar estimates of EF compared with standard volumes. Cathet Cardiovasc Intervent 2001;52:314–319. Published 2001 Wiley‐Liss, Inc.
Balloon atrial septostomy in end‐stage pulmonary hypertension guided by a novel intracardiac echocardiographic transducer
Authors: Moscucci Mauro , Dairywala Ismail T. , Chetcuti Stanley , Mathew Biju , Li Peng , Rubenfire Melvyn , Vannan Mani A. 
Published: August 2002

AbstractBlade and balloon atrial septostomy has been used to reduce cardiopulmonary symptoms and as a bridge to lung or heart lung transplant in primary pulmonary hypertension. Due to severe right atrial dilatation and resultant loss of anatomical landmarks, the procedure is technically difficult, and the reported postprocedure mortality rate varies between 5% and 50%. Among others, marked systemic desaturation and systemic hypotension presumably secondary to an excessively large atrial septal defect have been reported as causes of postprocedure death. We report a case where a novel intracardiac catheter‐based phased‐array 5.5–10 MHz transducer with spectral and color‐flow Doppler capabilities was used to assist a balloon atrial septostomy and to obtain hemodynamic data in a patient with end‐stage pulmonary hypertension. Cathet Cardiovasc Intervent 2001;52:530–534. © 2001 Wiley‐Liss, Inc.
Bioptome‐assisted simultaneous delivery of multiple coils for occlusion of the large patent ductus arteriosus
Authors: Kumar R. Krishna , Krishnan M.N. , Venugopal K. , Sivakumar Kothandam , Anil Sivadasan Radha 
Published: August 2002

AbstractWe describe a novel method that allows bioptome–assisted delivery of multiple Gianturco coils simultaneously for occlusion of the large patent ductus arteriosus (PDA). Two or more coils were intertwined at one end and held by a bioptome (5.2 Fr) and pulled into a short introducer. The coils were then deployed in the PDA via a long sheath (7–11 Fr) previously placed across the duct via the femoral vein. Twelve patients (6 months to 64 years; median, 10.5 years) with large PDAs (4.7 ± 1.3 mm; range, 3.1–8.4 mm; PA mean pressure, 40 ± 17 mm Hg; pulse pressure 63 ± 18 mm Hg) underwent bioptome‐assisted occlusion with multiple coils at our institutions. The procedure was uneventful in nine patients (fluoroscopy time, 6–23 min) and prolonged in three patients (fluoroscopy time, 26, 72, and 120 min) because of dislodgment of the coil mass and embolization of an additional coil. Successful coil deployment was feasible in all patients. Three patients required repeat coil deployment for flow elimination (hemolysis occurred in two). Flow elimination was demonstrated on the last follow‐up evaluation in all except two patients. One infant has developed significant left pulmonary artery stenosis. Bioptome‐assisted PDA occlusion using multiple coils delivered simultaneously may be a promising alternative to devices for transcatheter closure of large PDAs. Cathet Cardiovasc Intervent 2001;54:95–100. © 2001 Wiley‐Liss, Inc.
Safety and efficacy of repeat transradial access for cardiac catheterization procedures
Authors: Caputo Ronald P. , Simons Alan , Giambartolomei Alessandro , Grant William , Fedele Kathleen , Abraham Sunil , Felice Peter , Reger Mark J. , Walford Gary D. , Esente Paolo 
Published: August 2002

AbstractTo determine the safety and efficacy of repeat transradial cardiac catheterization, 1,362 consecutive transradial procedures were examined. Repeat transradial procedures were identified (group I, n = 73) and compared with index procedures (group II, n = 1,289). Baseline patient characteristics, procedure success rates (100% vs. 97.9%; P = NS), complication rates (0% vs. 0.08%; P = NS), and procedure times (23.9 ± 27.3 min vs. 18.2 ± 14.7 min; P = NS) were similar between groups. This study suggests that repeat transradial catheterization procedures can be performed safely and successfully in appropriately selected patients. Cathet Cardiovasc Intervent 2001;54:188–190. © 2001 Wiley‐Liss, Inc.
Therapy of postoperative stroke: Report of intra‐arterial thrombolysis of a hyperacute embolic stroke 5 days following CABG
Authors: Khasani Sina , Ramee Stephen R. , Felberg Robert A. 
Published: August 2002

AbstractIntra‐arterial (IA) recombinant tissue plasminogen activator (rt‐PA) is an investigational treatment for acute stroke. We report a case of IA thrombolysis of a hyperacute middle cerebral artery stroke 5 days after coronary artery bypass graft surgery. Despite a serious extracranial bleeding complication (hemothorax), immediate thrombolysis with IA rt‐PA led to near complete resolution of the neurological deficit and a favorable outcome. Cathet Cardiovasc Intervent 2001;54:339–341. © 2001 Wiley‐Liss, Inc.
Combined use of retrograde myocardial and distal coronary protection for last vessel intervention in an aortocoronary vein graft
Authors: Denk Stefan , Syeda Bonni , Beran Gilbert , Glogar Dietmar , Siostrzonek Peter 
Published: August 2002

AbstractFeasibility, safety, and clinical efficacy of the combined application of the PercuSurge system and the Myoprotect SSR device was demonstrated in a patient with high‐risk anatomy undergoing saphenous vein graft intervention. This combined approach of coronary and myocardial protection may be considered in high‐risk aortocoronary vein graft interventions. Cathet Cardiovasc Intervent 2001;54:342–345. © 2001 Wiley‐Liss, Inc.
A systematic evaluation of the benefits and hazards of variable selection in latent variable regression. Part II. Practical applications
Authors: Baumann K. , von Korff M. , Albert H. 
Published: August 2002

AbstractLeave‐multiple‐out cross‐validation (LMO‐CV) is compared to leave‐one‐out cross‐validation (LOO‐CV) as objective function in variable selection for four real data sets. Two data sets stem from NIR spectroscopy and two from quantitative structure–activity relationships. In all four cases, LMO‐CV outperforms LOO‐CV with respect to prediction quality, model complexity (number of latent variables) and model size (number of variables). The number of objects left out in LMO‐CV has an important effect on the final results. It controls both the number of latent variables in the final model and the prediction quality. The results of variable selection need to be validated carefully with a validation step that is independent of the variable selection. This step needs to be done because the internal figures of merit (i.e. anything that is derived from the objective function value) do not correlate well with the external predictivity of the selected models. This is most obvious for LOO‐CV. LOO‐CV without further constraints always shows the best internal figures of merit and the worst prediction quality. Copyright © 2002 John Wiley & Sons, Ltd.
Overall view of the use of chiral platinum(II) complexes as chiral derivatizing agents (CDAs) for the enantiodiscrimination of unsaturated compounds by 195Pt NMR
Authors: Uccello‐Barretta Gloria , Bernardini Raffaella , Balzano Federica , Salvadori Piero 
Published: August 2002

AbstractThe use of organometallic CDAs based on ethene‐platinum(II) complexes, covalent cis‐ and trans‐dichloro(Am)(ethylene)platinum(II), and ionic [PtCl3(C2H4)]−[AmH]+, containing primary and secondary amines, for the 195Pt NMR enantiodiscrimination of chiral unsaturated compounds is reviewed. Chirality 14:484–489, 2002. © 2002 Wiley‐Liss, Inc.
Chromatographic enantioseparation by cycloalkylcarbamate derivatives of cellulose and amylose
Authors: Kubota Takateru , Yamamoto Chiyo , Okamoto Yoshio 
Published: August 2002

AbstractCyclopentyl and (±)‐exo‐2‐norbornylcarbamates of cellulose and amylose were prepared and their chiral recognition abilities as chiral stationary phases for high‐performance liquid chromatography (HPLC) were evaluated. Among these carbamates, cellulose tris(cyclopentylcarbamate) and amylose tris((±)‐exo‐2‐norbornylcarbamate) showed particularly high chiral recognition, which is comparable to that of several well‐known phenylcarbamate derivatives. The chiral recognition mechanism of cellulose tris(cyclohexylcarbamate), which was previously found to be an effective chiral stationary phase for HPLC, was investigated using NMR spectroscopy. The derivative dissolved in chloroform exhibited the chiral discrimination of several enantiomers in NMR as well as in HPLC. For example, the 1,1′‐bi‐2‐naphthol enantiomers were distinctly discriminated in the 1H, 13C, and 2D‐NOESY spectra. Chirality 14:372–376, 2002. © 2002 Wiley‐Liss, Inc.
Model‐based predictions of BRCA1/2 mutation status in breast carcinoma patients treated at an academic medical center
Authors: Shannon Kristen M. , Lubratovich Marcie L. , Finkelstein Dianne M. , Smith Barbara L. , Powell Simon N. , Seiden Michael V. 
Published: August 2002

AbstractBACKGROUNDWomen with an existing breast carcinoma diagnosis who are found to carry a BRCA1/2 mutation have a substantial risk of developing both a contralateral breast carcinoma and ovarian carcinoma. In a newly diagnosed breast carcinoma patient, this genetic information may influence the management of her disease. To assess the volume of patients who may need genetic services at the time of diagnosis, the authors determined the proportion of women with newly diagnosed breast carcinoma at the study institution who would be eligible for genetic testing.METHODSFifty consecutive women with new breast carcinoma who were attending a multidisciplinary clinic were interviewed. Detailed, three‐generation pedigrees were collected for each patient by a genetic counselor. Three commonly used probability models were used to calculate each woman's predicted risk of harboring a germline BRCA1/2 mutation.RESULTSEleven of 50 patients (22% [95% confidence interval, 12–36%]) were calculated to have a ≥ 10% probability of carrying a BRCA1/2 mutation by at least one mathematic model and should have been offered genetic counseling that included the discussion of genetic testing. There were considerable discrepancies between probability calculations among the three mathematic models. One of the 11 patients who was eligible for genetic testing pursued genetic counseling within 12 months of diagnosis.CONCLUSIONSAt a large academic medical center, a substantial proportion of unselected women attending a multidisciplinary clinic were found to have a ≥ 10% risk of carrying a BRCA1/2 mutation. The actual number of patients eligible to receive BRCA1/2 genetic testing outweighs the number of patients seen for genetic counseling at the study institution. Finally, limited correlation was found between current predictive models. Cancer 2002;94:305–13. © 2002 American Cancer Society.
Results of the Lynn Sage Second‐Opinion Program for local therapy in patients with breast carcinoma
Authors: Clauson Jennifer , Hsieh Y. C. , Acharya Simbi , Rademaker Alfred W. , Morrow Monica 
Published: August 2002

AbstractBACKGROUNDThe treatment options of breast conservation therapy (BCT) and immediate reconstruction for patients with carcinoma of the breast have not been adopted widely. The objectives of this study were to determine how often a second opinion on the local therapy of breast carcinoma changed patient management and to identify factors predictive of remaining at the second‐opinion site for therapy.METHODSTwo hundred thirty‐one patients with intraductal carcinoma or Stage I and II breast carcinoma were reviewed retrospectively. At the time of the second opinion, patients completed a questionnaire regarding their initial surgical opinion and the reason for seeking consultation.RESULTSOnly 46% of patients had a complete discussion of treatment options prior to the second opinion. The second opinion changed management in 54 patients (20.3%). The most common finding was eligibility for BCT in patients who were offered only mastectomy. Definitive local therapy occurred at the second‐opinion site in 65.8% of patients. The only predictors of remaining at the second‐opinion site were insurance type (P = 0.008) and the patient's perception that options were not discussed at the initial opinion (P < 0.001).CONCLUSIONSSecond opinions provide useful information to patients and may change the management of their disease. They result in significant patient capture for an institution. Cancer 2002;94:889–94. © 2002 American Cancer Society.DOI 10.1002/cncr.10318
Influence of delay to diagnosis on prognostic indicators of screen‐detected breast carcinoma
Authors: Olivotto Ivo A. , Gomi Asako , Bancej Christina , Brisson Jacques , Tonita Jon , Kan Lisa , Mah Zeva , Harrison Marion , Shumak Rene 
Published: August 2002

AbstractBACKGROUNDAlthough delay to diagnosis after a breast screening abnormality causes anxiety, its effect on prognosis is unknown.METHODSUsing pooled data from five Canadian organized breast cancer screening programs, the authors used unconditional logistic regression to evaluate the effect of delay to diagnosis on prognostic indicators among 4465 women with invasive breast carcinoma diagnosed in the ipsilateral breast within 3 years of an abnormal screen performed during 1990–1996.RESULTSWomen with high‐suspicion screens (n = 1569) compared with those without (n = 2896) were more promptly investigated (median days from screen to diagnosis, 31 vs. 47; P ≤ 0.0001), had larger tumors (79.4% vs. 55.9% > 10 mm; P ≤ 0.0001), and were more likely to be lymph node positive (33.9% vs. 17.3%; P ≤ 0.0001). For delays beyond > 12 to ≤ 20 weeks, a linear trend of increased tumor size and lymph node positivity began to emerge. Controlling for suspicion, the authors found that odds ratios for tumor size greater than 10 mm were 0.9 (95% CI, 0.66–1.17), 1.2 (95% confidence interval [CI], 0.88–1.56), 1.5 (95% CI, 1.05–2.16), and 2.1 (95% CI, 1.15–3.86) for delays of > 12 to ≤ 20, > 20 to ≤ 52, > 52 to ≤ 104, and > 104 ≤ 156 weeks, respectively (ptrend ≤ 0.0001), compared with delays of > 4 to ≤ 12 weeks. Similarly, odds ratios for lymph node metastasis were 1.0 (95% CI, 0.67–1.42), 1.2 (95% CI, 0.84–1.69), 2.2 (95% CI, 1.48–3.15), and 3.2 (95% CI, 1.84–5.55) for the same time intervals (ptrend = 0.0033).CONCLUSIONSThe authors' findings suggest that delays to diagnosis of asymptomatic breast carcinoma of 6 to 12 months are associated with progression of breast carcinoma as measured by increasing risk of lymph node metastases and larger tumor size. A policy of early recall rather than biopsy for low suspicion mammographic abnormalities may introduce delays of this magnitude. The tendency to more expediently investigate women with high‐suspicion, worse prognosis screens (suspicion bias) obscures whether delays shorter than 20 weeks also worsen prognostic indicators. Suspicion bias should be considered when interpreting the effect of delay on prognosis. Cancer 2002;94:2143–50. © 2002 American Cancer Society.DOI 10.1002/cncr.10453
Incidence of cancer among patients with knee implants in Sweden, 1980–1994
Authors: Fryzek Jon P. , Ye Weimin , Signorello Lisa B. , Lipworth Loren , Blot William J. , Mclaughlin Joseph K. , Nyren Olof 
Published: August 2002

AbstractBACKGROUNDAs knee implants become more common, it is important to study their potential health risks. We investigated cancer occurrence in a nationwide population‐based cohort of 30,011 patients who underwent knee replacement surgery in Sweden from 1980 to 1994.METHODSPatients were followed from 1 year after the date of their surgery through December 31, 1995, accruing 122,616 person‐years of observation. The average follow‐up time was 4.3 years, with 2365 patients followed for 10 years or more.RESULTSOverall cancer incidence was not elevated compared with the general population of Sweden (standardized incidence ratio [SIR] = 1.03; 95% confidence interval [CI] = 0.98–1.08). A reduced rate for all respiratory cancers (SIR = 0.73; 95% CI = 0.59–0.91) and for lung cancer (SIR = 0.73; 95% CI = 0.58–0.91) was found among both men and women. Elevated rates were found for prostate (SIR = 1.20; 95% CI = 1.06–1.34) and bone cancer (SIR = 6.00; 95% CI = 1.24–17.52) in men. The bone cancer excess was based on three observed cases, two of which occurred at a site unrelated to the implant and the site of the third tumor is unknown. Rates of connective tissue cancer and leukemia–lymphoma were not elevated significantly among knee implant recipients. Long‐term follow‐up (≥ 10 years) did not show a significant excess risk for all cancer (SIR = 1.10; 95% CI = 0.86–1.38) or for any site‐specific cancer, including bone cancer, lymphoma, or leukemia. Subgroup analyses for patients with rheumatoid arthritis produced results similar to the overall results.CONCLUSIONSThis epidemiologic study of cancer risk among patients with knee implants is the largest to date. It provides evidence that the incidence of cancer among patients with knee implants is similar to that of the general population. Continued follow‐up of this cohort is warranted to evaluate further potential long‐term effects of these implants. Cancer 2002;94:3057–62. © 2002 American Cancer Society.DOI 10.1002/cncr.10580